Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Uroderma AB
AB
Active
Org 5568520588
Drottninggatan 18, 652 25
Karlstad
Medical specialists activities
·
NACE 8622
Est. 2011 · 15 years old
5 employees
Monitor
Share
Sweden
/
Companies
/
Medical specialists activities
/
Uroderma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
15M
11M
7M
4M
0M
2020: 7M
7M
2020
2021: 9M (+29% vs 2020)
9M
+29%
2021
2022: 11M (+22% vs 2021)
11M
+22%
2022
2023: 12M (+9% vs 2022)
12M
+9%
2023
2024: 11M (-8% vs 2023)
11M
-8%
2024
EBITDA
SEK millions
7M
6M
4M
2M
0M
2020: 3M
3M
2020
2021: 4M (+33% vs 2020)
4M
+33%
2021
2022: 6M (+50% vs 2021)
6M
+50%
2022
2023: 6M (0% vs 2022)
6M
0%
2023
2024: 5M (-17% vs 2023)
5M
-17%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
10 957
11 706
10 662
9 100
7 063
Staff expenses
—
—
—
—
—
EBITDA
4 789
5 722
5 691
4 111
2 989
Depreciation & amort.
−223
−220
−236
−363
−177
EBIT
4 566
5 502
5 455
3 748
2 812
Net financials
91
10
3
—
−1
Profit before tax
4 657
5 513
5 458
3 748
2 810
Tax
−1 000
−1 125
−1 687
−1 176
−766
Net profit
3 657
4 388
3 771
2 572
2 044
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
10 969
10 252
9 819
7 597
5 682
Equity
10 059
9 402
8 014
5 742
4 671
Long-term debt
0
0
0
0
0
Short-term debt
910
850
1 806
1 855
1 012
Total debt
910
850
1 806
1 855
1 012
Financial ratios
5-year trend
EBITDA margin
43,7 %
This company
15,8 %
Market median
This company
Market median
177% above market
2020
2024
Equity ratio
91,7 %
This company
38,2 %
Market median
This company
Market median
140% above market
2020
2024
Return on equity
36,4 %
This company
18,4 %
Market median
This company
Market median
98% above market
2020
2024
Net profit margin
33,4 %
This company
8,1 %
Market median
This company
Market median
312% above market
2020
2024
Asset turnover
1,00×
This company
1,12×
Market median
This company
Market median
11% below market
2020
2024
Debt / equity
0,09×
This company
0,62×
Market median
This company
Market median
85% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Uroderma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
